Literature DB >> 20182926

Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity.

Miran Kenk1, James T Thackeray, Stephanie L Thorn, Karan Dhami, Benjamin J Chow, Kathy J Ascah, Jean N DaSilva, Rob S Beanlands.   

Abstract

BACKGROUND: Altered sympathetic nervous system signaling is known to play a role in the cardiotoxicity of the anthracycline chemotherapeutic agents, but the interaction of pre- and postsynaptic function is not well understood. METHODS AND
RESULTS: Our aim was to study the noradrenergic signaling in an established rat model of adriamycin cardiotoxicity (15 mg/kg administered i.p. over 2 weeks) using radiotracers having potential applicability for imaging with positron emission tomography (PET). Ex vivo biodistribution was performed 1 and 3 weeks post-adriamycin treatment with the noradrenaline analogue [(11)C]meta-hydroxyephedrine ([(11)C]HED), beta-adrenergic receptor antagonist [(3)H]CGP12177, and phosphodiesterase-4 inhibitor (R)-[(11)C]rolipram. Cardiac function (echocardiographic parameters) and heart/body weight ratio were not affected. Myocardial retention of [(11)C]HED, [(3)H]CGP12177, and (R)-[(11)C]rolipram were unchanged 1 week post-adriamycin. Compared to controls, 3 weeks post-treatment [(3)H]CGP12177 uptake decreased (left ventricle free wall and septum; P < 0.05), while [(11)C]HED and (R)-[(11)C]rolipram uptake were unaffected. Following acute increase in myocardial noradrenaline levels with desipramine treatment, (R)-[(11)C]rolipram retention increased in the left atrium, right ventricle, left ventricle free wall and septum (P < 0.05) in vehicle-, but not adriamycin-treated animals.
CONCLUSION: Our results suggest that adriamycin-induced toxicity exhibits no change in presynaptic noradrenaline uptake, but decreased beta-adrenergic receptors in cardiac tissues, supporting a role for PET imaging of noradrenaline signaling in the study of anthracycline cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182926     DOI: 10.1007/s12350-009-9190-x

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  41 in total

Review 1.  Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin.

Authors:  Malgorzata Tokarska-Schlattner; Theo Wallimann; Uwe Schlattner
Journal:  C R Biol       Date:  2006-06-21       Impact factor: 1.583

2.  In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.

Authors:  Miran Kenk; Michael Greene; James Thackeray; Robert A deKemp; Mireille Lortie; Stephanie Thorn; Rob S Beanlands; Jean N DaSilva
Journal:  Nucl Med Biol       Date:  2006-11-16       Impact factor: 2.408

3.  Expression and regulation of human and rat phosphodiesterase type IV isogenes.

Authors:  P Engels; K Fichtel; H Lübbert
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

4.  Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats.

Authors:  J Tong; P K Ganguly; P K Singal
Journal:  Am J Physiol       Date:  1991-03

5.  Alterations in fatty acid metabolism in adriamycin cardiomyopathy.

Authors:  R S Beanlands; N A Shaikh; W H Wen; F Dawood; A M Ugnat; P R McLaughlin; R Carere; P P Liu
Journal:  J Mol Cell Cardiol       Date:  1994-01       Impact factor: 5.000

6.  Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit.

Authors:  A Calderone; J de Champlain; J L Rouleau
Journal:  J Mol Cell Cardiol       Date:  1991-03       Impact factor: 5.000

7.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

8.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

9.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749

10.  Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B.

Authors:  C D Manning; M M McLaughlin; G P Livi; L B Cieslinski; T J Torphy; M S Barnette
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

View more
  13 in total

1.  Dissecting myocardial signal transduction cascades: Sharp new insights from multi-tracer molecular imaging.

Authors:  Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2010-04       Impact factor: 5.952

Review 2.  Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.

Authors:  Ronny S Jiji; Christopher M Kramer; Michael Salerno
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

3.  Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography.

Authors:  Maira S Oliveira; Marcos B Melo; Juliana L Carvalho; Isabela M Melo; Mario Sl Lavor; Dawidson A Gomes; Alfredo M de Goes; Marilia M Melo
Journal:  J Cancer Sci Ther       Date:  2013

Review 4.  Cardiovascular imaging in cardio-oncology.

Authors:  Amir Abbas Mahabadi; Christoph Rischpler
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 5.  Comprehensive review on cardio-oncology: Role of multimodality imaging.

Authors:  Carol Chen-Scarabelli; Chad McRee; Massoud A Leesar; Fadi G Hage; Tiziano M Scarabelli
Journal:  J Nucl Cardiol       Date:  2016-05-25       Impact factor: 5.952

6.  Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging.

Authors:  James T Thackeray; Rob S Beanlands; Jean N Dasilva
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-20

7.  Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat.

Authors:  Nolwenn Merlet; Nicolas Piriou; Bertrand Rozec; Amandine Grabherr; Benjamin Lauzier; Jean-Noël Trochu; Chantal Gauthier
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 8.  Cardiorespiratory fitness in breast cancer patients: a call for normative values.

Authors:  Amanda B Peel; Samantha M Thomas; Kim Dittus; Lee W Jones; Susan G Lakoski
Journal:  J Am Heart Assoc       Date:  2014-01-13       Impact factor: 5.501

9.  Carvedilol Prevents Redox Inactivation of Cardiomyocyte Β1-Adrenergic Receptors.

Authors:  Misun Park; Susan F Steinberg
Journal:  JACC Basic Transl Sci       Date:  2018-08-28

10.  Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment.

Authors:  Nejka Potočnik; Martina Perše; Anton Cerar; Rade Injac; Žarko Finderle
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.